

REFERENCES

1. World Health Organization. Guidelines for the appropriate use of herbal medicines. Manila: WHO Publications, 1998: 1-4.
2. World Health Organization. Research guideline for evaluating the safety and efficacy of herbal medicines. Manila: WHO Regional Publications, 1993.
3. Newell CA, Herbal medicines, a guide for health-care professionals. London: The Pharmaceutical Press, 1996.
4. World Health Organization. Guidelines for the appropriate use of herbal medicines. Manila: WHO Publications, 1998: 15.
5. Moongkarndi P. Antiproliferation, antioxidation and induction of apoptosis by *Garcinia mangostana* (mangosteen) on SKBR3 human breast cancer cell line. *J Ethnopharmacol* 2004; 90: 161-166.
6. Williams P, Ongsakul M, Prodfoot J, Croft K, Bellin L. Mangostin inhibits the oxidative modification of human low density lipoprotein. *Free Radic Res* 1995; 23: 175-184.
7. Nwafor PA, Okwuasaba FK. Anti-nociceptive and anti-inflammatory effects of methanolic extract of *Asparagus pubescens* root in rodents. *J Ethnopharmacol* 2003; 84: 125-129.
8. Ozturk B, Apaydin S, Goldeli E, Ince I, Zeybek U. *Hypericum triquetrifolium* Turra. extract exhibits anti-inflammatory activity in the rat. *J Ethnopharmacol* 2002; 80: 207-209.
9. Mujumdar AM, Naik DG, Dandge CN, Puntambekar HM. Antiinflammatory activity of *Curcuma amada* Roxb. in albino rats. *Indian J Pharmacol* 2000; 32: 375-377.
10. Panthong A, Kanjanapothi D, Taesotikul T, Wongcome T, Reutrakul V. Anti-inflammatory and antipyretic properties of *Clerodendrum petasites* S. Moore. *J Ethnopharmacol* 2003; 85: 151-156.

11. Hazekamp A, Verpoorte R, Panthong A. Isolation of a bronchodilator flavonoid from the Thai medicinal plant *Clerodendrum petasites*. *J Ethnopharmacol* 2001; 78: 45-49.
12. Norkaew P. Anti-inflammatory, analgesic and antipyretic activities of Gamboge extract from *Garcinia hanburyi* Hook F. Thesis for Master of Science, Chiang Mai University, 2003.
13. Mitchell RN, Cotran RS. Acute and chronic inflammation. In: Kumar V, Cotran RS, Robbin SL (eds). Robbins basic pathology. 7th ed. Philadelphia: WB Saunders, 2003: 33.
14. Collins T. Acute and Chronic inflammation. In: Cotran RS, Kumar V, Collins T (eds). Robbins pathologic basis of disease. 6th ed. Philadelphia: WB Saunders, 1999: 50-88.
15. Demoly P. [Physiopathologic bases of ENT inflammation]. *Presse Med* 2001; 30 (39-40 Pt 2): 8-18.
16. Glass CK, Wilzturn JL. Atherosclerosis. the road ahead. *Cell*. 2001; 104: 503-516.
17. Chandrasoma P, Taylor CR. The acute inflammatory response. In: Chandrasoma P, Taylor CR (eds). Concise pathology. 2nd ed. East Norwalk: Appleton & Lange, 1995: 35-46.
18. Rankin JA. Biological mediators of acute inflammation. *AACN Clin Issues* 2004; 15(1): 3-17.
19. Brown E. Inflammation-part two. In: Gilbert HF (ed). Basic concepts in pathology: a student's survival guide. New York: McGraw-Hill, 1998: 206-208.
20. Chandrasoma P, Taylor CR. Chronic inflammation. In: Chandrasoma P, Taylor CR (eds). Concise pathology. 2nd ed. East Norwalk: Appleton & Lange, 1995: 69-77.
21. Jutel M, Watanabe T, Akdis M, Blaser K, Akdis CA. Immune regulation by histamine. *Curr Opin Immunol* 2002; 14(6): 735-40.
22. Hill SJ. Distribution, properties, and functional characteristics of three classes of histamine receptor. *Pharmacol Rev* 1990; 42(1): 45-83.

23. Gantz I, Schaffer M, DeValle J, *et al.* Molecular cloning of a gene encoding the histamine H₂ receptor. *Proc Natl Acad Sci U S A* 1991; 88(2): 429-33.
24. Liu C, Ma X, Jiang X, *et al.* Cloning and pharmacological characterization of a fourth histamine receptor (H₄) expressed in bone marrow. *Mol Pharmacol* 2001; 59(3): 420-6.
25. Morse KL, Behan J, Laz TM, *et al.* Cloning and characterization of a novel human histamine receptor. *J Pharmacol Exp Ther* 2001; 296(3): 1058-66.
26. Alguacil LF, Perez-Garcia C. Histamine H₃ receptor: a potential drug target for the treatment of central nervous system disorders. *Curr Drug Targets CNS Neurol Disord* 2003; 2(5): 303-13.
27. Repka-Ramirez MS. New concepts of histamine receptors and actions. *Curr Allergy Asthma Rep* 2003; 3(3): 227-31.
28. Fung-Leung WP, Thurmond RL, Ling P, Karlsson L. Histamine H₄ receptor antagonists: the new antihistamines? *Curr Opin Investig Drugs* 2004; 5(11): 1174-83.
29. Hancock AA, Brune ME. Assessment of pharmacology and potential anti-obesity properties of H₃ receptor antagonists/inverse agonists. *Expert Opin Investig Drugs* 2005; 14(3): 223-41.
30. Katzung BG, Julius DJ. Drugs with important action on smooth muscle. In: Katzung BG (ed). *Basic and Clinical pharmacology*. 8th ed. San Francisco: McGraw-Hill, 2001: 265-331.
31. Brown NJ, Roberts II LJ. Histamine, bradykinin and their antagonis. In: Hardman JG, Limbird LE (eds). *Goodman & Gilman's The pharmacological basis of therapeutics*. 10th ed. New York: McGraw-Hill, 1999: 645-667.
32. Mitchell RN, Cotran RS. Acute and chronic inflammation. In: Kumar V, Cotran RS, Robbin SL (eds). *Robbins basic pathology*. 7th ed. Philadelphia: WB Saunders, 2003: 47.
33. Repka-Ramirez MS, Baraniuk JN. Histamine in health and disease. *Clin Allergy Immunol* 2002; 17: 1-25.

34. Sanders-Bush E, Mayer SE. 5-Hydroxytryptamine (serotonin): receptor agonists and antagonists. In: Hardman JG, Limbird LE (eds). Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 269-290.
35. Racke K, Schworer H. Regulation of serotonin release from the intestinal mucosa. *Pharmacol Res* 1991; 23(1): 13-25.
36. Racke K, Reimann A, Schworer H, Kilbinger H. Regulation of 5-HT release from enterochromaffin cells. *Behav Brain Res* 1996; 73(1-2): 83-7.
37. Sommer C. Serotonin in pain and analgesia: actions in the periphery. *Mol Neurobiol* 2004; 30(2): 117-25.
38. Rang HP, Dale MM, Ritter JM. Other peripheral mediators: 5-hydroxytryptamine and purines. 3rd ed. London: Churchill Livingstone, 1995: 177-190.
39. O'Connor TM, O'Connell J, O'Brien DI, *et al.* The role of substance P in inflammatory disease. *J Cell Physiol* 2004; 201(2): 167-80.
40. Suzuki H. [Tachykininergic neurotransmission in the central nervous system]. *J Nippon Med Sch* 2002; 69(4): 322-7.
41. Foegh ML, Ramwell PW. The Eicosanoids: Prostaglandins, Thromboxanes, Leukotrienes, & related compound. In: Katzung BG (ed). Basic and Clinical Pharmacology. San Francisco: McGraw-Hill, 2001: 314-315.
42. Reid IA. Vasoactive peptides. In: Katzung BG (ed). Basic clinical pharmacology. 8th ed. New York: McGraw-Hill, 2001: 298-301.
43. Walker K, Perkins M, Dray A. Kinins and kinin receptors in the nervous system. *Neurochem Int* 1995; 26(1): 1-16; discussion 17-26.
44. Stadnicki A, Pastucha E, Nowaczyk G, *et al.* Immunolocalization and Expression of Kinin B1R and B2R Receptors in Human Inflammatory Bowel Disease. *Am J Physiol Gastrointest Liver Physiol* 2005.
45. Morissette G, Fortin JP, Otis S, Bouthillier J, Marceau F. A novel nonpeptide antagonist of the kinin B1 receptor: effects at the rabbit receptor. *J Pharmacol Exp Ther* 2004; 311(3): 1121-30.

46. Vellani V, Zachrisson O, McNaughton PA. Functional bradykinin B1 receptors are expressed in nociceptive neurones and are upregulated by the neurotrophin GDNF. *J Physiol* 2004; 560(Pt 2): 391-401.
47. Male D. Complement. In: Roitt I, Brostoff J, Male D (eds). *Immunology*. 6th ed. London: 2001: 54-60.
48. Mongar JL. Complement. In: Dale MM, Foreman JC (eds). *Text book of Immunopharmacology*. 2nd ed. London: Blackwell Scientific, 1989: 149-156.
49. Roberts II LJ, Morrow JD. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE (eds). *Goodman & Gilman's the pharmacological basis of therapeutics*. 10th ed. London: McGraw-Hill, 2001: 687-731.
50. Thomas G, Ramwell PW. Nitric oxide, donors, & inhibitors. In: Katzung BG (ed). *Basic and clinical pharmacology*. 8th ed. New York: McGraw-Hill, 2001: 326-331.
51. Morrow JD, Roberts II LJ. Eicosanoids and platelet-activating factor. In: Hardman JG, Limbird LE (eds). *Goodman & Gilman's the pharmacological basis of therapeutic*. 10th ed. McGraw-Hill, 2001: 669-680.
52. Abe M, Oka T, Hori T, Takahashi S. Prostanoids in the preoptic hypothalamus mediate systemic lipopolysaccharide-induced hyperalgesia in rats. *Brain Res* 2001; 916(1-2): 41-9.
53. Pang L, Knox AJ. Effect of interleukin-1 beta, tumour necrosis factor-alpha and interferon-gamma on the induction of cyclo-oxygenase-2 in cultured human airway smooth muscle cells. *Br J Pharmacol* 1997; 121(3): 579-87.
54. Furst DE, Hillson J. Aspirin and other nonsteroidol anti-inflammatory drugs. In: Koopman WJ (ed). *Arthritis and allied conditions*. 14th ed. Philadelphia: Lippincott Williams & Wilkins, 2001: 665-716.
55. Graham GG, Scott KF. Mechanism of action of paracetamol. *Am J Ther* 2005; 12(1): 46-55.

56. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmon DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. *Proc Natl Acad Sci USA* 2002; 99: 13926-13931.
57. Kontogiorgis CA, Hadjipavlou-Litina DJ. Non steroidal anti-inflammatory and anti-allergy agents. *Curr Med Chem* 2002; 9(1): 89-98.
58. Fantone JC, Ward PA. Inflammation. In: Rubin E, Farber JL (eds). Pathology. 3rd ed. Philadelphia: Lippincott-Raven, 1999: 37-75.
59. Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? *Biochem Pharmacol* 2001; 62(11): 1433-8.
60. Ankarath S, Raman R, Giannoudis PV. Non-steroidal anti-inflammatory drugs in orthopaedic practice: an update. *Current Orthopaedics* 2003; 17: 144-149.
61. Sung J, Russell RI, Nyeomans, *et al.* Non-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract. *J Gastroenterol Hepatol* 2000; 15 Suppl: G58-68.
62. Masferrer JL, Zweifol BS, Manning PT. Selective inhibition of inducible cyclooxygenase-2 in vivo is anti-inflammatory and nonulcerogenic. *Proc Natl Acad Sci USA*. 1994; 91: 3228-3232.
63. Coppelli G, Guaita E, Spaggiari S, Coruzzi G. Gastric effects of the selective cyclooxygenase-2 inhibitor, celecoxib in the rat. *Dig Liver dis* 2004; 36: 265-270.
64. Analgesic-antipyretic-antiinflammatory & related drug. [online]. Available http://quark.qmc.ufsc.br/qmcweb/artigos/dor/bonus/pain_killers (29 August 2000).
65. Ganong WF. Endocrinology, metabolism, & reproductive function: energy balance, metabolism, & nutrition. In: Ganong WF (ed). Review of medical physiology. 20th ed. New York: McGraw-Hill, 2001: 299-300.

66. Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for anti-inflammatory drug. *Proc Soc Exp Biol Med* 1962; 11: 544-547.
67. Vinegar R, Schreiber W, Hugo R. Biphasic development of carrageenin edema in rats. *J Pharmacol Exp Ther* 1969; 166(1): 96-103.
68. Di Rosa M. Biological properties of carrageenan. *J Pharm Pharmacol* 1972; 24(2): 89-102.
69. Di Rosa M, Ground JP, Willoughby DA. Studies of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine. *Journal of pathology* 1971; 104: 15-29.
70. Sedgwick AD, Willoughby DA. Animal models for testing drugs on inflammatory and hypersensitivity reactions. In: Dale MM, Foreman JC (eds). Textbook of immunology. 2nd ed. Oxford: Blackwell Scientific, 1989: 253-261.
71. Peck MJ, Piper PJ, Williams TJ. The effect of leukotrienes C₄ and D₄ on the microvasculature of guinea-pig skin. *prostaglandins* 1981; 21: 315-321.
72. DiMartino MJ, Campbell GK Jr, Wolff CE, Hanna N. The pharmacology of arachidonic acid-induced rat paw edema. *Agents Actions* 1987; 21(3-4): 303-305.
73. Swingle KF, Shideman FE. Phases of the inflammatory response to subcutaneous implantation of cotton pellet and their modification by certain anti-inflammatory agents. *J Pharmacol Exp Ther* 1972; 183(1): 226-234.
74. Firkin F, Chesterman C, Penington D, Rush B. White cells: Neutrophilia and Eosinophilia; Neutropenia and Agranulocytosis; Infectious Mononucleosis. In: de Gruchy's Clinical Hematology in Medical Practice. 5th ed. Australia: Blackwell Scientific, 1989: 216-235.
75. Nishikaze O, Takita H, Takase T. Activity of newly discovered protease in carrageenin-induced inflammation in rats. *IRC Medical Science, Biochemistry, Connective Tissue; Skin and Bone; Survey and Transplantation*. 1980; 8: 725.

76. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. *Pain* 1977; 4: 161-174.
77. Noble F, Smadja C, Valverde O, Maldonado R, Coric P, Turcaud S, Zaluski MCF, Roques BP. Pain-suppressive effects on various nociceptive stimuli (thermal, chemical electrical and inflammatory) of the first orally active enkephalin-metabolizing enzyme inhibitor RB 120. *Pain* 1997; 73: 383-391.
78. Hunskaar S, Fasmer OB, Hole K. Formalin test in mice, a useful technique for evaluating mild analgesics. *J Neurosci Meth* 1985; 14: 69-76.
79. Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. *Pain* 1987; 30(1): 103-114.
80. Shibata M, Ohkubo T, Takahashi H, Inoki R. Modified formalin test: characteristic biphasic pain response. *Pain* 1989; 38: 347-352.
81. Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. *Pain* 1992; 51(1): 5-17.
82. Loux JJ, DePalma PD, Yankell SL. Antipyretic testing of aspirin in rats. *Toxicol Appl Pharmacol* 1972; 22(4): 672-5.
83. Ganong WF. Functions of the nervous system: central regulation of visceral function. In: Ganong WF (ed). Review of medical physiology. 20th ed. New York: McGraw-Hill, 2001: 245-247.
84. OECD guideline for testing of chemical. Organization for economic cooperation and development, 1981.
85. OECD guideline for testing of chemical. Organization for economic cooperation and development. 2001.
86. Saralamp P, Tamsiririrkul P, Chuakul W, *et al*. Medicinal Plants in Siri Rukhachati Gardens. Bangkok: Amarin Printing Group, 1992.
87. Hegnauer R. Chemotaxonomie der Pflanzen, *Base: Birkhauser* 1962-1969; 1-5: 117-121.
88. สุภาภรณ์ ปิติพร. หน้่าบักกิงสมุนไพรรทางเลือกของผู้ป่วยมะเร็ง. พิมพ์ครั้งที่ 3. กรุงเทพฯ ฯ: เรือนแก้วการพิมพ์, 2545.

89. Thai Herbal Teas from Lampang medicinal plants conservation assembly.
[online]. Available <http://www.nervetouch.com/teas.html> (29 August 2000).
90. วิณา จิรัจฉริยากุล. สารต้านมะเร็งจากหญ้าปักกิ่ง. *จุลสารข้อมูลสมุนไพร* 2542; 16(3): 10-3.
91. เอื้อพร ไชยวรรณ, สุวรรณ เวชอภิกุล, วิรัตน์ นิวัฒน์นันท์, กนกพร นิวัฒน์นันท์. รายงานการวิจัยเรื่อง การศึกษาฤทธิ์ลดระดับน้ำตาลในเลือดของส่วนสกัดจากหญ้าปักกิ่ง (ตอนที่ 1) คณะเภสัชศาสตร์ มหาวิทยาลัยเชียงใหม่, 2544.
92. Herbal for healing cancers “alternative medicine for home remedies used”.
[online]. Available <http://www.simple-remedies.com/remedy-links/remedy-links/healing-remedies-gerbal-medicine.html>. (29 August 2000).
93. Jiratchariyakul W, Moongkarandi P, Okabe H, Frahm AW. Investigation of anticancer components from *Murdannia loriformis* (Hassk.) Rolla Rao et Kammathy. *Pharma Indochina* 20-23 May 1997.
94. ดาลัด เรื่องศิลป์, ธนิต สาขากุล. รายงานการวิจัยเรื่อง การศึกษาพฤษเคมีในหญ้าปักกิ่ง. กระบวนวิชาปัญหาพิเศษทางเภสัชเวท ภาควิชาเภสัชเวท คณะเภสัชศาสตร์ มหาวิทยาลัยเชียงใหม่, 2543.
95. นภาพร โออริยะกุล. รายงานการวิจัยเรื่อง การศึกษาทางพฤษเคมีของส่วนที่มีฤทธิ์ต้านการกลายของหญ้าปักกิ่ง คณะเภสัชศาสตร์ มหาวิทยาลัยเชียงใหม่, 2545.
96. Jiratchariyakul W, Okabe H, Frahm AW. A steroidal glycoside from *Murdannia loriformis* (Hassk.) Rolla Rao et Kammathy. *Thai J Phytopharm* 1996; 3 (1): 31-39.
97. Jiratchariyakul W, Okabe H, Moongkrandi P, Frahm AW. Cytotoxic glycosphingolipid from *Murdannia loriformis* (Hassk) Rolla Rao et Kammathy. *Thai J Phytopharm* 1998; 5: 10-20.
98. Narintorn A. Phytochemical study of anticancer components from *murdannia loriformis* (Hassk.) Rolla Rao et Kammathy. Thesis for Master of Science. Mahidol University, 1999.
99. Charoenkunathum W. Antimutagenicity and DT-diaphorase inducing activity of *Murdannia loriformis*. Thesis for Master of Science. Chiang Mai University, 1995.

100. Intiyot Y, Kinouchi T, Kataoka K, Arimochi H, Kuwahara T, Vinitketkumneun U, Ohnishi Y. Antimutagenicity of *Murdannia loriformis* in salmonella mutation assay and its inhibitory effects on azoxymethane-induced DNA methylation and aberrant crypt focus formation in male F344 rats. *J Med Invest* 2002; 49(1-2): 25-34.
101. Vinitketkumneun U, Charoenkunathum W, Kongtawelert P, Lertprasertsuke N, Picha P and Matsushima T. DT-diaphorase inducer activity of antimutagenic Thai medicinal plant, *Murdannia loriformis*. *J Herbs Spices Med Plants* 1996; 4(1): 45-52.
102. Intiyot Y. Effects of *Murdannia loriformis* extract on azoxymethane-induced DNA-adducts and aberrant crypt foci in rat colons. Thesis for Master of Science. Chiang Mai University, 2002.
103. Pomprasert S, Punturee K, Vinitketkumneun U. Anti-proliferative and cytotoxic effects of *Murdannia loriformis* on leukemic cell lines. *Chiang Mai Med Bull* 2001; 40(4): 195-203.
104. Mahidol University Annual Research Abstracts. "Human immune-mediated cytotoxicity of pressed juiced from *Murdannia loriformis* (Hassk). Rolla Rao et Kammathy. [online]. Available http://www.mahidol.ac.th/abstracts/annual_2000/0183.htm. (August 2002).
105. Herb for healing cancer. "Angle grass". [online]. Available <http://www.medherb.com>. (29 August 2000).
106. พิมลวรรณ ทัญญุทพิจารณ์, วัลลา งามนัฐจินดา, พรรณี พิเดช. การศึกษาความเป็นพิษเฉียบพลันของหญ้าปักกิ่งในหนูขาว. *สารศิริราช* 2534; 43: 548-62.
107. พิมลวรรณ ทัญญุทพิจารณ์, เพียงจิต สัตตบุศย์, พรรณี พิเดช. พิษเรื้อรังของหญ้าปักกิ่งในหนูขาว. *สารศิริราช* 2534; 43: 529-33.
108. สมสกุล วงศ์ปาลีย์. รายงานการวิจัยเรื่อง การศึกษาฤทธิ์ระงับปวดและฤทธิ์ต้านการอักเสบจากสารสกัดจากหญ้าปักกิ่ง, โครงการพัฒนาอัจฉริยภาพทางวิทยาศาสตร์สำหรับเด็กและเยาวชนระดับมัธยมศึกษาตอนปลายและปริญญาตรี สำนักงานพัฒนาวิทยาศาสตร์และเทคโนโลยีแห่งชาติ, 2546.

109. Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. *Cancer Metastasis Rev* 2004; 23(1-2): 63-75.
110. Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. *Semin Arthritis Rheum* 2002; 32 (3 Suppl 1): 25-32.
111. Steele VE, Hawk ET, Viner JL, Lubet RA. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. *Mutat Res* 2003; 523-524: 137-44.
112. Dai Y, Zhang X, Peng Y, Wang Z. The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma. *Gynecol Oncol* 2005; 97(1): 96-103.
113. Wang W, Bergh A, Damber JE. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. *Clin Cancer Res* 2005; 11(9): 3250-6.
114. Yamamoto DS, Viale PH. Cyclooxygenase-2: from arthritis treatment to new indications for the prevention and treatment of cancer. *Clin J Oncol Nurs* 2003; 7(1): 21-9.
115. Cornetta AJ, Russell JP, Cunnane M, Keane WM, Rothstein JL. Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis. *Laryngoscope* 2002; 112(2): 238-42.
116. Eschwege P, de Ledinghen V, Camilli T, *et al.* [Arachidonic acid and prostaglandins, inflammation and oncology]. *Presse Med* 2001; 30(10): 508-10.
117. Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. *Breast Cancer Res* 2005; 7(4): R422-35.
118. Bessey O, Lowry OH, Brock MJ. Method for the determination of alkaline phosphatase with five cubic millimeters of serum. *J Biol Chem* 1946; 164: 321-329.
119. Milano F, Serrano JS, Pascual J, Sancibrain M. Effects of GABA on gastric acid secretion and ulcer formation in rats. *Life Sci* 1987; 41(13): 1651-1658.

120. Teotino U, Friz LP, Gandini A, Dellabella D. Thio derivatives of 2,3-dihydro-4H-1,3-benzoxazin-4-one synthesis and pharmacological properties. *J Med Chem* 1963; 55: 248-250.
121. Hinz B, Brune K. Cyclooxygenase-2--10 years later. *J Pharmacol Exp Ther* 2002; 300(2): 367-75.
122. Beaugerie L, Thieffin G. [Gastrointestinal complications related to NSAIDs]. *Gastroenterol Clin Biol* 2004; 28 Spec No 3: C62-72.
123. Crunkhon P, Meacock SCR. Mediators of the inflammation induced in the rat paw by carrageenan. *British Journal of Pharmacology* 1971; 42: 392-402.
124. Di Rosa M, Sorrentino L. The mechanism of the inflammatory effect of carrageenan. *European Journal of Pharmacology* 1968; 4: 340-342.
125. Di Rosa M, Willoughby DA. Screens for anti-inflammatory drugs. *J Pharm Pharmacol* 1971; 24(3): 297-298.
126. Ueno A, Naraba H, Ikeda Y, *et al.* Intrinsic prostacyclin contributes to exudation induced by bradykinin or carrageenin: a study on the paw edema induced in IP-receptor-deficient mice. *Life Sci* 2000; 66(12): PL155-60.
127. Bertolini A, Ottani A, Sandrini M. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. *Current Medical Chemistry* 2002; 9: 1033-1043.
128. Suleyman H, Yildirim D, Aslan A, *et al.* An investigation of the antiinflammatory effects of an extract from *Cladonia rangiformis* HOFFM. *Biol Pharm Bull* 2002; 25(1): 10-3.
129. Ismail TS, Gopalakrishnan S, Begum VH, Elango V. Anti-inflammatory activity of *Salacia oblonga* Wall. and *Azima tetraantha* Lam. *J Ethnopharmacol* 1997; 56(2): 145-52.
130. Diegelmann RF, Evans MC. Wound healing: an overview of acute, fibrotic and delayed healing. *Front Biosci* 2004; 9: 283-9.

131. Bailey PJ, Sturm A, Lopez-Ramos B. A biochemical study of the cotton pellet granuloma in the rat. Effects of dexamethasone and indomethacin. *Biochem Pharmacol* 1982; 31(7): 1213-8.
132. Whiteley PJ, Needleman P. Mechanism of enhanced fibroblast arachidonic acid metabolism by mononuclear cell factor. *J Clin Invest* 1984; 74(6): 2249-53.
133. Berne RM, Levy MN. The adrenal glands. In: Physiology. St. Louis Missouri: Mosby-year book, 1998: 930-950.
134. Ionac M, Parnham MJ, Plauchithiu M, Brune K. Oxaceprol, an atypical inhibitor of inflammation and joint damage. *Pharmacol Res* 1996; 33(6): 367-73.
135. Boyd JR. Drug facts and comparison. Missouri: JB Lippincott, 1982: 33-39.
136. Salmon JA, Higgs GA. Prostaglandins and leukotrienes as inflammatory mediators. *Br Med Bull* 1987; 43(2): 285-96.
137. Naik SR, Sheth UK. Studies on two new derivatives of N-arylalkyl-o-ethoxybenzamides: Part II--biochemical studies on their anti-inflammatory activity. *Indian J Exp Biol* 1978; 16(11): 1175-9.
138. Rainsford KD. Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damage. *Agents Actions* 1993; 39 Spec No: C24-6.
139. Burian M, Geisslinger G. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. *Pharmacol Ther* 2005; 107(2): 139-54.
140. Rosland JH, Tjolsen A, Maehle B, Hole K. The formalin test in mice: effect of formalin concentration. *Pain* 1990; 42(2): 235-42.
141. Ito S, Okuda-Ashitaka E, Minami T. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. *Neurosci Res* 2001; 41(4): 299-332.
142. Samad TA, Moore KA, Sapirstein A, *et al.* Interleukin-1 β -mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. *Nature* 2001; 410(6827): 471-5.

143. Seybold VS, Jia YP, Abrahams LG. Cyclo-oxygenase-2 contributes to central sensitization in rats with peripheral inflammation. *Pain* 2003; 105(1-2): 47-55.
144. Beiche F, Scheuerer S, Brune K, Geisslinger G, Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. *FEBS Lett* 1996; 390(2): 165-9.
145. Rivot JP, Montagne-Clavel J, Besson JM. Subcutaneous formalin and intraplantar carrageenan increase nitric oxide release as measured by in vivo voltammetry in the spinal cord. *Eur J Pain* 2002; 6(1): 25-34.
146. Kawamata T, Omote K. Activation of spinal N-methyl-D-aspartate receptors stimulates a nitric oxide/cyclic guanosine 3, 5-monophosphate/glutamate release cascade in nociceptive signaling. *Anesthesiology* 1999; 91(5): 1415-24.
147. Blatteis CM, Sehic E, Li S. Pyrogen sensing and signaling: old views and new concepts. *Clin Infect Dis* 2000; 31 Suppl 5: S168-77.
148. Oka T. Prostaglandin E₂ as a mediator of fever: the role of prostaglandin E (EP) receptors. *Front Biosci* 2004; 9: 3046-57.
149. Blatteis CM, Li S, Li Z, Feleder C, Perlik V. Cytokines, PGE₂ and endotoxic fever: a re-assessment. *Prostaglandins Other Lipid Mediat* 2005; 76(1-4): 1-18.
150. Kuraishi Y, Ushikubi F. [Pain, fever and prostanoids]. *Nippon Yakurigaku Zasshi* 2001; 117(4): 248-54.
151. Romanovsky A, Almeida MC, Aronoff DM, *et al.* Fever and hypothermia in systemic inflammation: recent discoveries and revisions. *Front Biosci* 2005; 10: 2193-216.
152. Ushikubi F, Segi E, Sugimoto Y, *et al.* Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP₃. *Nature* 1998; 395 (6699): 281-4.